Related Experiment Video
Updated: May 7, 2026

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
Published on: November 16, 2016
STAT1-L351F is associated with enhanced interferon signaling and susceptibility to Talaromyces marneffei infection
Yuchen Gu1,2, Haimei Zhang3, Qiaozi Lin4
1Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Introduction:
Talaromyces marneffei can cause life-threatening disseminated infection, yet the immune alterations linking STAT1 gain-of-function (GOF) variants, including the previously reported L351F site, to talaromycosis remain incompletely defined.
Methods:
We investigated STAT1-L351F in a four-member pedigree in which disease was restricted to the proband, combining human immunophenotyping, mechanistic assays, and an in vivo infection model. Systemic immune status was assessed by serum cytokine profiling, and peripheral blood mononuclear cell (PBMC) antifungal control was quantified using CFU-based ex vivo growth assays with T. marneffei, with extension to Cryptococcus neoformans and Candida albicans. STAT1 signaling was evaluated in HEK293T cells expressing STAT1-WT or STAT1-L351F by measuring IFN-α/β/γ-induced STAT1 phosphorylation and interferon-stimulated response element/gamma-activated sequence (ISRE/GAS) reporter activity. Wild-type and Stat1-L351F knock-in mice were challenged intranasally with T. marneffei and analyzed for lung fungal burden, histopathology, immune profiling, and bulk lung transcriptomics; infected Stat1-L351F mice additionally received ruxolitinib to probe the impact of JAK inhibition on infection-associated myeloid responses.
Results:
The proband displayed an interferon-skewed cytokine milieu, and patient PBMCs supported increased ex vivo growth of T. marneffei and C. neoformans, whereas C. albicans did not show a consistent increase. STAT1-L351F was associated with increased IFN-induced STAT1 phosphorylation and enhanced ISRE/GAS reporter activity, consistent with a hyper-responsive interferon signaling state in this system. In vivo, female Stat1-L351F mice developed higher lung fungal burden and more severe pathology at 16 days post-infection, accompanied by reduced NKT-cell frequencies and broad transcriptomic remodeling characterized by type I interferon-biased signatures together with dysregulated myeloid/neutrophil effector and IL-17-related programs. Ruxolitinib partially attenuated infection-associated expansion of myeloid-derived suppressor cell subsets.
Discussion:
Overall, STAT1-L351F was associated with impaired antifungal control, selective ex vivo permissiveness to distinct fungal pathogens, and altered IL-17-linked immune programs during T. marneffei infection, providing a multi-layered framework for understanding how dysregulated STAT1 signaling may reshape antifungal immunity across human, cell-based, and in vivo systems.
Insights
STAT1 gain-of-function (GOF) variants impair antifungal immunity, leading to increased susceptibility to Talaromyces marneffei infection. This study reveals how STAT1-L351F dysregulates immune responses, impacting fungal control.
Area of Science:
- Immunology
- Genetics
- Infectious Diseases
Background:
- Talaromyces marneffei causes disseminated infections, but the immune mechanisms involving STAT1 gain-of-function (GOF) variants are not fully understood.
- STAT1 GOF variants, like L351F, are linked to increased susceptibility to fungal infections.
Purpose of the Study:
- To investigate the immune alterations associated with the STAT1-L351F variant in a human pedigree and an in vivo model.
- To elucidate the impact of STAT1-L351F on antifungal immunity against Talaromyces marneffei and other fungal pathogens.
Main Methods:
- Human immunophenotyping, serum cytokine profiling, and ex vivo antifungal growth assays with patient peripheral blood mononuclear cells (PBMCs).
- Mechanistic assays in HEK293T cells to assess STAT1 signaling.
- In vivo studies using Stat1-L351F knock-in mice infected with T. marneffei, including transcriptomic analysis and JAK inhibition with ruxolitinib.
Main Results:
- The proband exhibited an interferon-skewed cytokine profile and increased susceptibility of PBMCs to T. marneffei and Cryptococcus neoformans ex vivo.
- STAT1-L351F demonstrated hyper-responsive interferon signaling.
- Stat1-L351F mice showed increased lung fungal burden, severe pathology, altered immune cell frequencies (reduced NKT cells), and dysregulated immune programs.
Conclusions:
- STAT1-L351F is associated with impaired antifungal control and selective permissiveness to fungal pathogens.
- Dysregulated STAT1 signaling reshapes antifungal immunity, impacting IL-17-related immune programs.
- This study provides a framework for understanding STAT1 GOF variants in fungal infections.
More Related Videos
11:21Forward Genetics Screens Using Macrophages to Identify Toxoplasma gondii Genes Important for Resistance to IFN-γ-Dependent Cell Autonomous Immunity
Published on: March 12, 2015
10:00High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Related Concept Videos
Non-LTR Retrotransposons
Inhibitors of Viral Protein Synthesis
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Intracellular Signaling Affects Focal Adhesions
Some...
The JAK-STAT Signaling Pathway